title: Over-tube is preferable to free-hand technique to avoid recurrence of varices after endoscopic injection sclerotherapy. Prospective randomized trial.
abstract: One hundred and two patients undergoing sclerotherapy of esophageal varices, using 5% ethanolamine oleate, were randomly allocated to either the over-tube (O-T) or the free-hand (F-H) group, and 100 patients could be followed at monthly intervals for a period of 30.8 +/- 14.7 months (mean +/- SD) after the varices had been eradicated. Endoscopy performed one month after the final session of sclerotherapy revealed circumferential ulcers and scarring in the lower esophagus in 42 of 50 patients (84%) in the O-T group and in 16 of 50 patients (32%) of the F-H group, the difference being statistically significant (P less than 0.01). In the remaining 8 and 34 patients in the O-T and the F-H groups, respectively, a partly fibrotic residual mucosa was seen. There was a recurrence of the varices in the residual mucosa in 14 (28%) in the F-H group during the mean follow-up period of 25.6 months, while there were five patients (10%) with a recurrence of varices in the O-T group, the difference being statistically significant (P less than 0.05). The survival rates showed no statistical significance. Two patients in the F-H group had recurrent bleeding. We conclude that the over-tube technique of sclerosing esophageal varices reduces the rate of recurrence of the varices, in the long term follow-up, and after formation of a circumferential scarring in the lower esophagus.
authors.affiliation: Department of Surgery II, Kyushu University Faculty of Medicine, Fukuoka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kitano
authors.forename: H
authors.initials: H
authors.lastname: Yamaga
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: M
authors.initials: M
authors.lastname: Hashizume
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D004932:Esophageal and Gastric Varices / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D004945:Esophagoscopy; D006801:Humans; D011446:Prospective Studies; D012008:Recurrence; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods*; D015996:Survival Rate